Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

48.87
+0.54001.12%
Pre-market: 49.380.5100+1.04%08:01 EDT
Volume:1.30M
Turnover:63.10M
Market Cap:8.20B
PE:125.88
High:49.03
Open:48.05
Low:47.64
Close:48.33
52wk High:55.67
52wk Low:25.17
Shares:167.76M
Float Shares:155.00M
Volume Ratio:1.11
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.53
PE(LYR):34.17

Loading ...

Alkermes schedules first-quarter results conference call and webcast

Reuters
·
Apr 22

Alkermes reports sustained Phase 2 alixorexton benefits in narcolepsy type 1 study

Reuters
·
Apr 16

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients With Narcolepsy Type 1 at the American Academy of Neurology (Aan) 2026 Annual Meeting

THOMSON REUTERS
·
Apr 16

Alkermes announces publication of 56-week post hoc analysis of Lybalvi

TIPRANKS
·
Apr 14

Alkermes says 56-week analysis links Lybalvi to improved schizophrenia negative symptoms

Reuters
·
Apr 14

Findings From Long-Term Analysis of the Effects of Lybalvi® (Olanzapine and Samidorphan) on Negative Symptoms of Schizophrenia Published in the Journal of Clinical Psychiatry

THOMSON REUTERS
·
Apr 14

Alkermes Plc : Mizuho Raises Target Price to $53 From $45

THOMSON REUTERS
·
Apr 10

Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Alkermes (ALKS)

TIPRANKS
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Alkermes Public to $36 From $34, Maintains Neutral Rating

MT Newswires Live
·
Apr 09

Alkermes EVP, CLO David Joseph Gaffin disposes of USD 70,309 in shares

Reuters
·
Apr 07

Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)

TIPRANKS
·
Apr 04

Mizuho Securities Sticks to Their Buy Rating for Alkermes (ALKS)

TIPRANKS
·
Apr 02

Alkermes EVP R&D, CMO Craig Hopkinson disposes of shares worth $0.3 million

Reuters
·
Apr 02

TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)

TIPRANKS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

Eli Lilly Diversifies from Weight-Loss Drugs to Sleep Disorders with Up to $7.8 Billion Centessa Acquisition

Deep News
·
Apr 01

BUZZ-Alkermes rises as it starts late-stage trials of sleep disorder drug

Reuters
·
Apr 01

Alkermes announces initiation of Brilliance Studies

TIPRANKS
·
Apr 01

Alkermes launches Phase 3 Brilliance trials of alixorexton in narcolepsy type 1, 2

Reuters
·
Apr 01